Physician profile
Ven C Chiang
NPI 1447367453
$4,448.43
in general payments reported to CMS, 2019-2025
22 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $347 · 2021: $501 · 2022: $687 · 2023: $844 · 2024: $820 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $844.42 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $700.74 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $621.55 | 2020-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $563.74 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Travere Therapeutics, INC. | $330.22 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $247.95 | 2019-2021 | |
| Vifor Pharma, INC. | $134.48 | 2019-2023 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $134.28 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $112.63 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $108.91 | 2021-2023 | Ultomiris |
| Ani Pharmaceuticals, INC. | $101.16 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $95.66 | 2019 | |
| Ardelyx, INC. | $81.27 | 2024-2025 | Ibsrela |
| Amgen INC. | $77.29 | 2019-2022 | |
| Akebia Therapeutics INC | $61.93 | 2019-2025 | Vafseo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $61.20 | 2023-2024 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $59.72 | 2020-2022 | |
| Bard Peripheral Vascular, INC. | $37.04 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.89 | 2022 | |
| Nxstage Medical, INC. | $17.57 | 2019 | |
| Lilly USA, LLC | $16.38 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $15.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ven Chiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.